Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Baxter
McKesson
Moodys
Express Scripts

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,623,087

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,623,087
Title:Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
Abstract: A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.
Inventor(s): Zhang; Ying (Woodbuy, MN), Fenn; Percy T. (St. Paul, MN), Johnson; Peter R. (Eagan, MN)
Assignee: 3M Innovative Properties Company (St. Paul, MN)
Application Number:14/361,787
Patent Claims:1. A medical device comprising: an array of microneedles; and a coating on or within at least a portion of the microneedles, wherein the coating comprises: a peptide therapeutic agent; and an amino acid, wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu.sup.22,25, Leu.sup.23,28,31, Aib.sup.29, Lys.sup.26,30]hPTHrP(1-34)NH.sub.2.

2. The medical device of claim 1, wherein the coating is substantially free of sorbitol.

3. The medical device of claim 1, wherein the amino acid is histidine.

4. The medical device of claim 3, wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 2:1.

5. The medical device of claim 4, wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 1.5:1.

6. The medical device of claim 3, wherein the histidine stabilizes the peptide therapeutic agent in the coating.

7. The medical device of claim 1, wherein the molar ratio of the amino acid to the peptide therapeutic agent is less than 2:1.

8. The medical device of claim 7, wherein the molar ratio of the amino acid to the peptide therapeutic agent is in a range from 0.5:1 to 55:1.

9. The medical device of claim 1, wherein the amino acid is histidine, arginine, or lysine.

10. The medical device of claim 1, wherein the amino acid is present in the coating in a range from 0.1 to 15 percent by weight, based on the total weight of the coating.

11. The medical device of claim 1, wherein the array of microneedles comprises a dissolvable matrix material, or wherein at least some of the microneedles are hollow.

12. A method of making a medical device comprising microneedles, the method comprising: providing an aqueous composition comprising a peptide therapeutic agent, an amino acid, and a buffer, wherein the peptide therapeutic agent and the amino acid both have a net positive charge in the aqueous composition; contacting the microneedles with the aqueous composition; and volatilizing a portion of the aqueous composition to provide a coating on at least a portion of the microneedles, wherein the coating comprises at least the peptide therapeutic agent and the amino acid, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu.sup.22,25, Leu.sup.23,28,31, Aib.sup.29, Lys.sup.26,30]hPTHrP(1-34)NH.sub.2.

13. The method of claim 12, wherein the aqueous composition has a pH in a range from 3 to 11.

14. The method of claim 12, wherein the amino acid is histidine, and wherein the molar ratio of the histidine to the peptide therapeutic agent in the aqueous composition is less than 2:1.

15. The method of claim 12, wherein the buffer comprises phosphate, acetate, citrate, or tris(hydroxymethyl)aminomethane.

16. The method of claim 12, wherein the amino acid is histidine, arginine, or lysine.

17. The method of claim 12, wherein the aqueous composition or the coating is substantially free of sorbitol.

18. A method of stabilizing a peptide therapeutic agent on or within an array of microneedles, the method comprising incorporating the peptide therapeutic agent and an amino acid on or within the array of microneedles, wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu.sup.22,25, Leu.sup.23,28,31, Aib.sup.29, Lys.sup.26,30]hPTHrP(1-34)NH.sub.2.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Colorcon
McKinsey
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.